Saved content diff

Before

This page is a Ministry of Health, Labour and Welfare announcement regarding influenza HA vaccine manufactured by the Chemical and Serum Therapeutic Research Institute. The institute had failed to properly report discrepancies between approval documents and actual manufacturing practices, leading to a shipment suspension request in September. After review, authorities determined the vaccine's quality and safety were not significantly affected. The Infectious Diseases Division of the Health Science Council recommended approving shipments to prevent supply shortages and control influenza. Consequently, the shipment suspension was lifted on October 21, 2015.

After

This page announces the Ministry of Health, Labour and Welfare's decision regarding influenza HA vaccine manufactured by the Chemical and Serum Therapy Research Institute. The ministry had requested suspension of shipments in September due to discrepancies between approval documentation and manufacturing practices. Following detailed review, no significant impact on product quality and safety was identified. The Infectious Disease Division of the Health Science Council concluded that shipment should be permitted to prevent influenza transmission and avoid supply shortages. Consequently, the ministry lifted the shipment suspension order on the announced date.